Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
|Articles|August 11, 2017
Lab Line Is Designed for Developing Drug Implant Technology
The Thermo Scientific Pharma mini implant line is built around the Thermo Scientific Pharma mini HME twin-screw micro compounder.
The Thermo Scientific Pharma mini implant line is an integrated solution for polymer-based drug implant development and production using hot-melt extrusion (HME). Built around the Thermo Scientific Pharma mini HME twin-screw micro compounder, the continuous, automated production line minimizes formulation development time. The line is also designed to allow contract research and manufacturing organizations to develop and optimize small-scale formulations before engaging in larger-scale production.
Components of the line include:
- A containment valve to add the API and the polymer, designed to protect the operator from exposure to the API and prevent contamination of the API
- A gravimetric feeder to deliver the API/polymer into the micro compounder for heating and mixing before the melt is extruded through a die that creates a continuous filament
- New bi-axial lasers that measure the thickness or diameter of the filament to adjust the stretching or “take-off” speed of the conveyor belt
- Proprietary equipment that cuts the filament to a desired implant length while maintaining “roundness” without deforming the implant shape.
Source:
Related to this article
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Trending on Pharmaceutical Technology
1
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
2
Why Impurity Deficiencies Keep Repeating: AAPS PharmSci 360 2026
3
AAPS PharmSci 360: How USP Is Tackling the Novel Excipient Roadblock
4
Why Drug Shortages Average 5+ Years: PharmTech Explained
5